IRCT1138901151556N12
Completed
Phase 2
A double - blind placebo controlled traial of tamoxifen added to litihium in patint with acute mania
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Mania episode.
- Sponsor
- Tehran University of Medical Sciences
- Enrollment
- 40
- Status
- Completed
- Last Updated
- 8 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •patients aged between 18 and 49 wioll be eligible to participate, as they meet the DSM\-IV criteria for a current manic episode, on the basis of a clinical interview by two academician psychiatrists. In addition, a score of at least 20 points on the YoungMania Rating Scale will be required representing at least a moderate\-to\-severe mania.
- •Exclusion criteria: Other diagnosis in Axix 1, substance dependence, severe medical problems and lactating and pregnant women.
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 2
In this study the effectiveness of a Hair tablet will be studied in women with thinning of hair.CTRI/2018/03/012868Atlantic Coast Brands
Completed
Not Applicable
A double-blinded randomised controlled trial of the effects of sodium citrate on olfactory thresholdsISRCTN50895907niversity Hospitals of Leicester NHS Trust (UK)100
Completed
Not Applicable
.A.-N30N30PER-002-96ABORATORIOS BAGO DEL PERU S.A.,
Active, not recruiting
Phase 1
A randomized, double-blind, placebo controlled clinical trial to find out the approbiate daily oral dose of vitamin D in patients with liver cirrhosis.decompensated and compensated liver cirrhosisMedDRA version: 16.1Level: LLTClassification code 10024667Term: Liver cirrhosisSystem Organ Class: 100000004871Therapeutic area: Diseases [C] - Digestive System Diseases [C06]EUCTR2012-001449-42-ATMedizinische Universität Graz, Kl. Abt. f. Endokrinoloie u. Stoffwechsel & Kl. Abt. f. Gastroenterologie u. Hepatologie100
Completed
Phase 2
A double blind placebo controlled clinical trial to evaluate the efficacy and safety of Shatavari in Menstrual irregularityHealth Condition 1: null- Menstrual irregularityCTRI/2011/06/001804The Himalaya Drug Company50